Novo’s High-Dose Wegovy Gets Green Light From EU Drug Panel

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than the standard dosage.

The European Medicines Agency’s drug review committee recommended allowing the new high-dose shot based on the results from large clinical trials in people with obesity, with and without diabetes, Novo said in a statement. The committee’s backing means the shot could be available early in the new year, pending final approval from the European Commission, Novo said.